Biotest Pharmaceuticals Corp. (BPC), a wholly owned US subsidiary of Biotest AG, has entered into a strategic long-term manufacturing, supply, and license agreement with ADMA Biologics, Inc.(ADMA).

Under the terms of the agreement, ADMA has agreed to purchase exclusively from BPC its worldwide requirements of RSV (Respiratory Syncytial Virus) Immune Globulin manufactured from human plasma containing RSV antibodies. The initial term of the agreement is for ten years.

BPC will receive payment for manufacturing services provided under the agreement as well as a percentage royalty on ADMA’s product revenues up to a specified maximum. In exchange, BPC has agreed to provide manufacturing services and granted ADMA a license to use BPC’s proprietary fractionation and purification manufacturing process for Intravenous Immune Globulin.

"We are very pleased to partner with ADMA on their lead product candidate.  Our ability to provide specialized contract manufacturing services will enable us to diversify our future revenue sources,” stated Jordan Siegel, chief eExecutive officer of BPC.

Biotest Pharmaceuticals Corporation, a wholly owned subsidiary of Biotest AG, researches, develops and manufactures biotherapeutic products with a specialization in immunology and haematology.

Biotest AG is a provider of pharmaceutical and biotherapeutic drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialized primarily in the areas of application of clinical immunology, haematology and intensive medicine.